187 related articles for article (PubMed ID: 21508803)
1. Reactivity profiles of broadly neutralizing anti-HIV-1 antibodies are distinct from those of pathogenic autoantibodies.
Singh H; Henry KA; Wu SS; Chruscinski A; Utz PJ; Scott JK
AIDS; 2011 Jun; 25(10):1247-57. PubMed ID: 21508803
[TBL] [Abstract][Full Text] [Related]
2. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
Alam SM; McAdams M; Boren D; Rak M; Scearce RM; Gao F; Camacho ZT; Gewirth D; Kelsoe G; Chen P; Haynes BF
J Immunol; 2007 Apr; 178(7):4424-35. PubMed ID: 17372000
[TBL] [Abstract][Full Text] [Related]
3. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity.
Scherer EM; Zwick MB; Teyton L; Burton DR
AIDS; 2007 Oct; 21(16):2131-9. PubMed ID: 18090039
[TBL] [Abstract][Full Text] [Related]
4. Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10.
Finton KA; Larimore K; Larman HB; Friend D; Correnti C; Rupert PB; Elledge SJ; Greenberg PD; Strong RK
PLoS Pathog; 2013; 9(9):e1003639. PubMed ID: 24086134
[TBL] [Abstract][Full Text] [Related]
5. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.
Haynes BF; Fleming J; St Clair EW; Katinger H; Stiegler G; Kunert R; Robinson J; Scearce RM; Plonk K; Staats HF; Ortel TL; Liao HX; Alam SM
Science; 2005 Jun; 308(5730):1906-8. PubMed ID: 15860590
[TBL] [Abstract][Full Text] [Related]
6. Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies.
Zhu Z; Qin HR; Chen W; Zhao Q; Shen X; Schutte R; Wang Y; Ofek G; Streaker E; Prabakaran P; Fouda GG; Liao HX; Owens J; Louder M; Yang Y; Klaric KA; Moody MA; Mascola JR; Scott JK; Kwong PD; Montefiori D; Haynes BF; Tomaras GD; Dimitrov DS
J Virol; 2011 Nov; 85(21):11401-8. PubMed ID: 21880764
[TBL] [Abstract][Full Text] [Related]
7. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies.
Yang G; Holl TM; Liu Y; Li Y; Lu X; Nicely NI; Kepler TB; Alam SM; Liao HX; Cain DW; Spicer L; VandeBerg JL; Haynes BF; Kelsoe G
J Exp Med; 2013 Feb; 210(2):241-56. PubMed ID: 23359068
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H
J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228
[TBL] [Abstract][Full Text] [Related]
9. 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity.
Kobie JJ; Alcena DC; Zheng B; Bryk P; Mattiacio JL; Brewer M; Labranche C; Young FM; Dewhurst S; Montefiori DC; Rosenberg AF; Feng C; Jin X; Keefer MC; Sanz I
PLoS One; 2012; 7(4):e35356. PubMed ID: 22530008
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes.
Matyas GR; Wieczorek L; Beck Z; Ochsenbauer-Jambor C; Kappes JC; Michael NL; Polonis VR; Alving CR
AIDS; 2009 Oct; 23(16):2069-77. PubMed ID: 19710597
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies.
Nakowitsch S; Quendler H; Fekete H; Kunert R; Katinger H; Stiegler G
AIDS; 2005 Nov; 19(17):1957-66. PubMed ID: 16260901
[TBL] [Abstract][Full Text] [Related]
12. Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).
Joos B; Trkola A; Kuster H; Aceto L; Fischer M; Stiegler G; Armbruster C; Vcelar B; Katinger H; Günthard HF
Antimicrob Agents Chemother; 2006 May; 50(5):1773-9. PubMed ID: 16641449
[TBL] [Abstract][Full Text] [Related]
13. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.
Li D; Liu J; Zhang L; Xu T; Chen J; Wang L; Zhao Q
Virol Sin; 2015 Dec; 30(6):449-56. PubMed ID: 26715302
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane.
Montero M; Gulzar N; Klaric KA; Donald JE; Lepik C; Wu S; Tsai S; Julien JP; Hessell AJ; Wang S; Lu S; Burton DR; Pai EF; Degrado WF; Scott JK
J Virol; 2012 Mar; 86(6):2930-41. PubMed ID: 22238313
[TBL] [Abstract][Full Text] [Related]
15. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
[TBL] [Abstract][Full Text] [Related]
16. Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.
Zhang MY; Vu BK; Choudhary A; Lu H; Humbert M; Ong H; Alam M; Ruprecht RM; Quinnan G; Jiang S; Montefiori DC; Mascola JR; Broder CC; Haynes BF; Dimitrov DS
J Virol; 2008 Jul; 82(14):6869-79. PubMed ID: 18480433
[TBL] [Abstract][Full Text] [Related]
17. Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection.
Bunnik EM; van Gils MJ; Lobbrecht MS; Pisas L; van Nuenen AC; Schuitemaker H
Virology; 2009 Aug; 390(2):348-55. PubMed ID: 19539340
[TBL] [Abstract][Full Text] [Related]
18. Anti-HIV-1 antibodies 2F5 and 4E10 interact differently with lipids to bind their epitopes.
Franquelim HG; Chiantia S; Veiga AS; Santos NC; Schwille P; Castanho MA
AIDS; 2011 Feb; 25(4):419-28. PubMed ID: 21245727
[TBL] [Abstract][Full Text] [Related]
19. Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies.
Sánchez-Martínez S; Lorizate M; Katinger H; Kunert R; Nieva JL
AIDS Res Hum Retroviruses; 2006 Oct; 22(10):998-1006. PubMed ID: 17067270
[TBL] [Abstract][Full Text] [Related]
20. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data.
Vcelar B; Stiegler G; Wolf HM; Muntean W; Leschnik B; Mehandru S; Markowitz M; Armbruster C; Kunert R; Eibl MM; Katinger H
AIDS; 2007 Oct; 21(16):2161-70. PubMed ID: 18090042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
